Rebecka Hjort1, Josefin E Löfvenborg1, Emma Ahlqvist2, Lars Alfredsson1, Tomas Andersson1,3, Valdemar Grill4, Leif Groop2,5, Elin P Sørgjerd6, Tiinamaija Tuomi5,7,8, Bjørn Olav Åsvold9,10, Sofia Carlsson1. 1. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 2. Department of Clinical Sciences in Malmö, Clinical Research Centre, Lund University, Malmö, Sweden. 3. Center for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden. 4. Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. 5. Finnish Institute of Molecular Medicine, Helsinki University, Helsinki, Finland. 6. HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway. 7. Division of Endocrinology, Abdominal Center, Helsinki University Hospital, Research Program for Diabetes and Obesity, University of Helsinki, Helsinki, Finland. 8. Folkhälsan Research Center, Helsinki, Finland. 9. Department of Endocrinology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 10. K.G. Jebsen Center for Genetic Epidemiology, NTNU, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.
Abstract
OBJECTIVE: We investigated potential interactions between body mass index (BMI) and genotypes of human leukocyte antigen (HLA), TCF7L2-rs7903146, and FTO-rs9939609 in relation to the risk of latent autoimmune diabetes in adults (LADA) and type 2 diabetes. METHODS: We pooled data from two population-based studies: (i) a Swedish study with incident cases of LADA [positive for glutamic acid decarboxylase autoantibodies (GADA); n = 394) and type 2 diabetes (negative for GADA; n = 1290) and matched controls without diabetes (n = 2656) and (ii) a prospective Norwegian study that included incident cases of LADA (n = 131) and type 2 diabetes (n = 1901) and 886,120 person-years of follow-up. Analyses were adjusted for age, sex, physical activity, and smoking. Interaction between overweight (BMI ≥ 25 kg/m2) and HLA/TCF7L2/FTO high-risk genotypes was assessed by attributable proportion due to interaction (AP). RESULTS: The combination of overweight and high-risk genotypes of HLA, TCF7L2, and FTO was associated with pooled relative risk (RRpooled) of 7.59 (95% CI, 5.27 to 10.93), 2.65 (95% CI, 1.97 to 3.56), and 2.21 (95% CI, 1.60 to 3.07), respectively, for LADA, compared with normal-weight individuals with low/intermediate genetic risk. There was a significant interaction between overweight and HLA (AP, 0.29; 95% CI, 0.10 to 0.47), TCF7L2 (AP, 0.31; 95% CI, 0.09 to 0.52), and FTO (AP, 0.38; 95% CI, 0.15 to 0.61). The highest risk of LADA was seen in overweight individuals homozygous for the DR4 genotype [RR, 26.76 (95% CI, 15.42 to 46.43); AP, 0.58 (95% CI, 0.32 to 0.83) (Swedish data)]. Overweight and TCF7L2 also significantly interacted in relation to type 2 diabetes (AP, 0.26; 95% CI, 0.19 to 0.33), but no interaction was observed with high-risk genotypes of HLA or FTO. CONCLUSIONS: Overweight interacts with HLA high-risk genotypes but also with genes associated with type 2 diabetes in the promotion of LADA.
OBJECTIVE: We investigated potential interactions between body mass index (BMI) and genotypes of human leukocyte antigen (HLA), TCF7L2-rs7903146, and FTO-rs9939609 in relation to the risk of latent autoimmune diabetes in adults (LADA) and type 2 diabetes. METHODS: We pooled data from two population-based studies: (i) a Swedish study with incident cases of LADA [positive for glutamic acid decarboxylase autoantibodies (GADA); n = 394) and type 2 diabetes (negative for GADA; n = 1290) and matched controls without diabetes (n = 2656) and (ii) a prospective Norwegian study that included incident cases of LADA (n = 131) and type 2 diabetes (n = 1901) and 886,120 person-years of follow-up. Analyses were adjusted for age, sex, physical activity, and smoking. Interaction between overweight (BMI ≥ 25 kg/m2) and HLA/TCF7L2/FTO high-risk genotypes was assessed by attributable proportion due to interaction (AP). RESULTS: The combination of overweight and high-risk genotypes of HLA, TCF7L2, and FTO was associated with pooled relative risk (RRpooled) of 7.59 (95% CI, 5.27 to 10.93), 2.65 (95% CI, 1.97 to 3.56), and 2.21 (95% CI, 1.60 to 3.07), respectively, for LADA, compared with normal-weight individuals with low/intermediate genetic risk. There was a significant interaction between overweight and HLA (AP, 0.29; 95% CI, 0.10 to 0.47), TCF7L2 (AP, 0.31; 95% CI, 0.09 to 0.52), and FTO (AP, 0.38; 95% CI, 0.15 to 0.61). The highest risk of LADA was seen in overweight individuals homozygous for the DR4 genotype [RR, 26.76 (95% CI, 15.42 to 46.43); AP, 0.58 (95% CI, 0.32 to 0.83) (Swedish data)]. Overweight and TCF7L2 also significantly interacted in relation to type 2 diabetes (AP, 0.26; 95% CI, 0.19 to 0.33), but no interaction was observed with high-risk genotypes of HLA or FTO. CONCLUSIONS: Overweight interacts with HLA high-risk genotypes but also with genes associated with type 2 diabetes in the promotion of LADA.
Authors: Rebecka Hjort; Josefin E Löfvenborg; Emma Ahlqvist; Lars Alfredsson; Tomas Andersson; Valdemar Grill; Leif Groop; Elin P Sørgjerd; Tiinamaija Tuomi; Bjørn Olav Åsvold; Sofia Carlsson Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Maria C Harpsøe; Saima Basit; Mikael Andersson; Nete M Nielsen; Morten Frisch; Jan Wohlfahrt; Ellen A Nohr; Allan Linneberg; Tine Jess Journal: Int J Epidemiol Date: 2014-03-07 Impact factor: 7.196
Authors: Diana L Cousminer; Emma Ahlqvist; Rajashree Mishra; Mette K Andersen; Alessandra Chesi; Mohammad I Hawa; Asa Davis; Kenyaita M Hodge; Jonathan P Bradfield; Kaixin Zhou; Vanessa C Guy; Mikael Åkerlund; Mette Wod; Lars G Fritsche; Henrik Vestergaard; James Snyder; Kurt Højlund; Allan Linneberg; Annemari Käräjämäki; Ivan Brandslund; Cecilia E Kim; Daniel Witte; Elin Pettersen Sørgjerd; David J Brillon; Oluf Pedersen; Henning Beck-Nielsen; Niels Grarup; Richard E Pratley; Michael R Rickels; Adrian Vella; Fernando Ovalle; Olle Melander; Ronald I Harris; Stephen Varvel; Valdemar E R Grill; Hakon Hakonarson; Philippe Froguel; John T Lonsdale; Didac Mauricio; Nanette C Schloot; Kamlesh Khunti; Carla J Greenbaum; Bjørn Olav Åsvold; Knud B Yderstræde; Ewan R Pearson; Stanley Schwartz; Benjamin F Voight; Torben Hansen; Tiinamaija Tuomi; Bernhard O Boehm; Leif Groop; R David Leslie; Struan F A Grant Journal: Diabetes Care Date: 2018-09-25 Impact factor: 19.112
Authors: Rebecka Hjort; Josefin E Löfvenborg; Emma Ahlqvist; Lars Alfredsson; Tomas Andersson; Valdemar Grill; Leif Groop; Elin P Sørgjerd; Tiinamaija Tuomi; Bjørn Olav Åsvold; Sofia Carlsson Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Jun-Yu Chen; Tao Xiong; Ya-Ru Sun; Juan Cong; Jing-Shuai Gong; Lei Peng; Yu-Wang Rong; Zi-Yao Wang; Qing Chang Journal: Ann Transl Med Date: 2022-09
Authors: Maria J Redondo; Megan V Warnock; Ingrid M Libman; Laura E Bocchino; David Cuthbertson; Susan Geyer; Alberto Pugliese; Andrea K Steck; Carmella Evans-Molina; Dorothy Becker; Jay M Sosenko; Fida Bacha Journal: Diabetes Care Date: 2021-07-29 Impact factor: 17.152